Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Jump to:
loading...
Preferred Name

Osimertinib Mesylate
Synonyms
Definitions

The mesylate salt form of osimertinib, a third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, osimertinib covalently binds to and inhibits the activity of numerous mutant forms of EGFR, including the secondarily-acquired resistance mutation T790M, L858R, and exon 19 deletions, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.
ID

http://purl.obolibrary.org/obo/NCIT_C170266
CAS_Registry

1421373-66-1
code

C170266
Contributing_Source

CTRP

FDA
definition

The mesylate salt form of osimertinib, a third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, osimertinib covalently binds to and inhibits the activity of numerous mutant forms of EGFR, including the secondarily-acquired resistance mutation T790M, L858R, and exon 19 deletions, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.
Display_Name

Osimertinib Mesylate
FDA_UNII_Code

RDL94R2A16
in_subset

http://purl.obolibrary.org/obo/NCIT_C63923

http://purl.obolibrary.org/obo/NCIT_C116977

http://purl.obolibrary.org/obo/NCIT_C116978
label

Osimertinib Mesylate
NCI_META_CUI

CL1382757
Preferred_Name

Osimertinib Mesylate
prefixIRI

NCIT:C170266
prefLabel

Osimertinib Mesylate
Semantic_Type

Pharmacologic Substance
subClassOf

http://purl.obolibrary.org/obo/NCIT_C2167

http://purl.obolibrary.org/obo/NCIT_C129825
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display